image
Healthcare - Medical - Devices - NASDAQ - US
$ 38.7
6.14 %
$ 5.87 B
Market Cap
50.92
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BRKR stock under the worst case scenario is HIDDEN Compared to the current market price of 38.7 USD, Bruker Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BRKR stock under the base case scenario is HIDDEN Compared to the current market price of 38.7 USD, Bruker Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one BRKR stock under the best case scenario is HIDDEN Compared to the current market price of 38.7 USD, Bruker Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BRKR

image
$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
3.37 B REVENUE
13.56%
253 M OPERATING INCOME
-42.07%
114 M NET INCOME
-73.36%
251 M OPERATING CASH FLOW
-28.22%
-1.76 B INVESTING CASH FLOW
-439.05%
1.23 B FINANCING CASH FLOW
735.88%
980 M REVENUE
13.33%
72.1 M OPERATING INCOME
5.87%
13.9 M NET INCOME
-66.43%
190 M OPERATING CASH FLOW
394.53%
-60.5 M INVESTING CASH FLOW
10.50%
-74.9 M FINANCING CASH FLOW
-2674.07%
Balance Sheet Bruker Corporation
image
Current Assets 2.05 B
Cash & Short-Term Investments 183 M
Receivables 566 M
Other Current Assets 1.3 B
Non-Current Assets 3.75 B
Long-Term Investments 0
PP&E 815 M
Other Non-Current Assets 2.94 B
3.16 %9.74 %22.46 %14.03 %50.61 %Total Assets$5.8b
Current Liabilities 1.28 B
Accounts Payable 234 M
Short-Term Debt 32.5 M
Other Current Liabilities 1.01 B
Non-Current Liabilities 2.71 B
Long-Term Debt 2.18 B
Other Non-Current Liabilities 530 M
5.86 %25.42 %54.63 %13.27 %Total Liabilities$4.0b
EFFICIENCY
Earnings Waterfall Bruker Corporation
image
Revenue 3.37 B
Cost Of Revenue 1.72 B
Gross Profit 1.65 B
Operating Expenses 1.4 B
Operating Income 253 M
Other Expenses 139 M
Net Income 114 M
4b4b3b3b3b3b2b2b2b2b1b1b500m500m003b(2b)2b(1b)253m(139m)114mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
49.00% GROSS MARGIN
49.00%
7.52% OPERATING MARGIN
7.52%
3.36% NET MARGIN
3.36%
6.35% ROE
6.35%
1.95% ROA
1.95%
3.07% ROIC
3.07%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bruker Corporation
image
250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 114 M
Depreciation & Amortization 184 M
Capital Expenditures -115 M
Stock-Based Compensation 25.3 M
Change in Working Capital 0
Others 0
Free Cash Flow 136 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bruker Corporation
image
Wall Street analysts predict an average 1-year price target for BRKR of $76.8 , with forecasts ranging from a low of $72 to a high of $80 .
BRKR Lowest Price Target Wall Street Target
72 USD 86.05%
BRKR Average Price Target Wall Street Target
76.8 USD 98.32%
BRKR Highest Price Target Wall Street Target
80 USD 106.72%
Price
Max Price Target
Min Price Target
Average Price Target
85858080757570706565606055555050454540403535May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.08% DIVIDEND YIELD
0.05 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.250.250.200.200.150.150.100.100.050.050.000.000.040.040.040.040.040.040.050.050.050.050.040.040.040.040.040.040.050.050.050.040.040.040.040.040.040.050.050.050.040.160.040.160.040.160.040.160.040.160.040.160.050.200.050.200.050.200.0520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Bruker Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
194 K USD 1
6-9 MONTHS
296 K USD 1
9-12 MONTHS
0 USD 0
Bought
1.04 M USD 2
0-3 MONTHS
5.01 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world's first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. This first-of-a-kind ultra-high field magnet and spectrometer pushes the boundaries of what is possible in the field of NMR research and opens a new chap. businesswire.com - 3 days ago
Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent' configuration. This novel Fourier 80 ‘Multi-Talent' system represents a major advancement in permanent magnet-based FT-NMR technology, as its unique, next-generation capabilities meet the evolving needs. businesswire.com - 3 days ago
Bruker Introduces Breakthrough d-DNP Polarizer: Stock to Gain? BRKR announces first successful customer installation of novel d-DNP Polarizer at UCSF. zacks.com - 1 week ago
Bruker Announces Introduction of Revolutionary d-DNP Polarizer for MRI Research and for Dynamic Nuclear Polarization Liquids NMR SAN FRANCISCO--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation today announced the introduction of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop at the University of California San Francisco (UCSF) Hyperpolarized MRI Technology Resource Center. The first customer installation of this innovative technology has been successfully completed, marking a milestone in hyperpolarized MRI for preclinical research. businesswire.com - 1 week ago
Bruker Stock to Benefit From the Launch of X4 POSEIDON Benchtop XRM BRKR unveils X4 POSEIDON advanced XRM for 3D microscopy in industrial and scientific applications. zacks.com - 1 month ago
Bruker Launches X4 POSEIDON™ Advanced X-Ray Microscope for Three-Dimensional Microscopy in Industrial and Scientific Applications KONTICH, Belgium--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announces the launch of the new X4 POSEIDON™, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). This innovative benchtop XRM system offers advanced capabilities comparable to larger, floor-standing systems to make high-resolution 3D X-ray microscopy accessible for demanding XRM applications in industrial applications and scientific research. The X4 POSEIDON features a high-end X-ray. businesswire.com - 1 month ago
Bruker Spatial Biology to Announce Groundbreaking Advances at AGBT 2025 BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting. Bruker Spatial Biology will announce the following four innovations that underscore Bruker's leading commitment to advancing spatial biology with pioneering, best-in-class platforms: the first and only Whole Transcriptome Panel (WTX) on the subcellular resolution CosMx Sp. businesswire.com - 1 month ago
Bruker Appoints Laura Francis to its Board of Directors BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company s. businesswire.com - 1 month ago
Bruker Announces Quarterly Dividend BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on March 28, 2025 to stockholders of record as of March 17, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new a. businesswire.com - 1 month ago
Bruker Corporation to Present at Upcoming Investor Conferences BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences: Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York City Thursday, February 27, 2025, at 2:30 p.m. Eastern Time TD Cowen 45th Annual Health Care Conference in Boston, MA Wednesday, March 5, 2025, at 11:10 a.m. Eastern Time Barclays 27th Annual Global Healthcare Conference in Miami, FL Tuesday, March 11, 2025, at 2:30 p.m. Eas. businesswire.com - 1 month ago
Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls Bruker delivers better-than-expected earnings and revenues in the fourth quarter of 2024. zacks.com - 1 month ago
Bruker Corporation (BRKR) Q4 2024 Earnings Call Transcript Bruker Corporation (NASDAQ:BRKR ) Q4 2024 Results Conference Call February 13, 2025 8:30 AM ET Company Participants Joe Kostka - Director, Investor Relations Frank Laukien - President and CEO Gerald Herman - Executive Vice President and CFO Conference Call Participants Puneet Souda - Leerink Partners Elizabeth Speyer - Citigroup Salem Salem - Barclays Brandon Couillard - Wells Fargo Madeline Mollman - Wolfe Research Tycho Peterson - Jefferies Subbu Nambi - Guggenheim Securities Operator Good day, and welcome to the Bruker Corporation Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. seekingalpha.com - 1 month ago
8. Profile Summary

Bruker Corporation BRKR

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 5.87 B
Dividend Yield 0.08%
Description Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Contact 40 Manning Road, Billerica, MA, 01821 https://www.bruker.com
IPO Date Aug. 4, 2000
Employees 11396
Officers Mr. Thomas Bures Chief Accounting Officer Dr. Mark R. Munch Ph.D. Corporate Executive Vice President and President of Bruker Nano Group & Corporate Mr. Juergen Srega President of Bruker CALID Group & Bruker Daltonics Division Dr. Falko Busse Ph.D. President of Bruker BioSpin Group Mr. J. Brent Alldredge J.D. Senior Vice President, General Counsel, Secretary & Global Head of Compliance Mr. Gerald N. Herman CPA Executive Vice President & Chief Financial Officer Dr. Frank H. Laukien Ph.D. Chairman, Chief Executive Officer & President Dr. Burkhard Prause Ph.D. President and Chief Executive Officer of Bruker Energy & Supercon Technologies, Inc.